Drug Approval | October 18, 2023
Glenmark receives ANDA approval for Apremilast Tablets
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Lupin enters into BTA with Lupin Manufacturing Solutions
He has 37 years of experience in API Intermediaries, Pharma and Chemicals industr
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Subscribe To Our Newsletter & Stay Updated
